OSI-906 (Linsitinib) 化学構造
分子量: 421.49

高品質保証

カスタマーフィードバック(3)

Quality Control & MSDS

製品説明

  • Compare IGF-1R Inhibitors
    IGF-1R製品生物活性の比較
  • 研究分野

製品の説明

生物活性

製品説明 OSI-906(Linsitinib)は、IGF-IRとIrの選択的な阻害剤で、IC50 がそれぞれ 35 nM と 75 nMです。
ターゲット IGF-1R InsR
IC50 35 nM 75 nM [1]
In vitro試験 OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. [1]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
A4-Fuk M2SyOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nMTWlEPTB;MD6wNlgxPiEQvF2= MYfTRW5ITVJ?
KS-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTBwMEO4N|Uh|ryP NFnNOnJUSU6JRWK=
TE-11 NEDTc|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17JfmlEPTB;MD6wO|gzOiEQvF2= MXTTRW5ITVJ?
EW-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofsTWM2OD1yLkC4OVg2KM7:TR?= NYnUdoNNW0GQR1XS
HMV-II MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWWzXIlrUUN3ME2wMlA5QDR4IN88US=> MWPTRW5ITVJ?
COLO-205 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\0R4tKSzVyPUCuNVA1PTRizszN MnfBV2FPT0WU
ES1 NIGwPVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\rOYFKSzVyPUCuNVA3QTZizszN MoPqV2FPT0WU
GDM-1 NYnGPJZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTBwMUO2O|Ih|ryP MYrTRW5ITVJ?
ML-2 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjmcYRpUUN3ME2wMlE2QDl4IN88US=> M4TkZnNCVkeHUh?=
Saos-2 Mo\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDlVZdKSzVyPUCuNVY2OjZizszN MU\TRW5ITVJ?
NCI-H1355 NVnPRmZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonPTWM2OD1yLkG4NVM2KM7:TR?= MX7TRW5ITVJ?
G-401 M{D0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTBwMUiyN{DPxE1? M37ZN3NCVkeHUh?=
EW-16 M1rRdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPTTWM2OD1yLkG4O|c4KM7:TR?= MnvPV2FPT0WU
EW-7 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjRSJhQUUN3ME2wMlE5QDhzIN88US=> MYfTRW5ITVJ?
NCI-H727 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWmzPJV3UUN3ME2wMlE6Pzl2IN88US=> Mn;WV2FPT0WU
LCLC-97TM1 NY\VN|JiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPXTWM2OD1yLkKwPVU2KM7:TR?= NEPle2hUSU6JRWK=
NCI-H650 NWf3bms{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTBwMkGzPFQh|ryP MmnCV2FPT0WU
NCI-H2122 MnfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTBwMkOyPVkh|ryP NG[4VHdUSU6JRWK=
SK-N-DZ MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYf4VZJ4UUN3ME2wMlI{Pjl6IN88US=> MXTTRW5ITVJ?
HT-29 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zJZWlEPTB;MD6yOFI1QCEQvF2= MUXTRW5ITVJ?
LB771-HNC MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HwbWlEPTB;MD6yOVkyPSEQvF2= M2fuXXNCVkeHUh?=
HT-144 M3G5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH[wcWNKSzVyPUCuNlYyQTFizszN NX3pe4VwW0GQR1XS
LAN-6 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkf5TWM2OD1yLkK2N|Q5KM7:TR?= M{nRdXNCVkeHUh?=
EW-18 Mn7qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTBwMkewNFEh|ryP MWLTRW5ITVJ?
LS-1034 NGnJfIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLXelZsUUN3ME2wMlI4OTN{IN88US=> M1jTW3NCVkeHUh?=
EW-11 M2\FRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTBwMki0N|Ih|ryP MY\TRW5ITVJ?
SNU-C1 M2X5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHrZpZKSzVyPUCuNlk{OTNizszN M3vEWHNCVkeHUh?=
RS4-11 NH\3N2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjWNnZKSzVyPUCuN|M4PThizszN MoOzV2FPT0WU
ES4 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzVb5pVUUN3ME2wMlQyODN6IN88US=> MlTuV2FPT0WU
COLO-320-HSR NGrOdllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTBwNEGzOlgh|ryP NITNV4NUSU6JRWK=
NB10 NHjXTmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rXVGlEPTB;MD60OVQ{PyEQvF2= M4X5UHNCVkeHUh?=
BFTC-905 NY\adopKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXhTVBjUUN3ME2wMlQ3PzV6IN88US=> NWDGe2dGW0GQR1XS
A375 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XFfGlEPTB;MD60O|YyPyEQvF2= NHXzTo9USU6JRWK=
SJRH30 NXHafmYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvjNZRKSzVyPUCuOVA5OjJizszN MXvTRW5ITVJ?
NOS-1 NHn0XWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfLXnY5UUN3ME2wMlUzOjZ5IN88US=> NWrvXFJDW0GQR1XS
SIG-M5 M3LKdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHsSopKSzVyPUCuOVM2PTdizszN NXfHNYlTW0GQR1XS
DOK Mn;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\1TWM2OD1yLkW1OkDPxE1? NWPo[lZrW0GQR1XS
NB69 NVO4c49yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTBwNUiyOVch|ryP NET5[FBUSU6JRWK=
SK-NEP-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nEZ2lEPTB;MD62NFI{PiEQvF2= NIHE[plUSU6JRWK=
SK-MM-2 Ml7DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfsV4FKSzVyPUCuOlU1QTFizszN NWH3ZXU5W0GQR1XS
NCI-H358 MkPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;GNmlEPTB;MD62O|A5OiEQvF2= Mme2V2FPT0WU
RH-1 MojCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7MZYpKSzVyPUCuO|Q5PTlizszN NXXReVd{W0GQR1XS
NH-12 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVf6SJZ5UUN3ME2wMlc3ODR4IN88US=> NX\teXVPW0GQR1XS
TE-12 M3;tOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTnTWM2OD1yLke2OFg3KM7:TR?= NFzGRYRUSU6JRWK=
COLO-668 NYrtPFFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjsT3pKSzVyPUCuPFQ3PjZizszN NGT3XGFUSU6JRWK=
PANC-08-13 M17LbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjWTWM2OD1yLki2N|c4KM7:TR?= M1HsdXNCVkeHUh?=
HCC2998 NVLSVXF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLuWWxlUUN3ME2wMlg5OjZ|IN88US=> M2rBeHNCVkeHUh?=
ABC-1 NF;qd5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXG1ZVNuUUN3ME2wMlkxOzV{IN88US=> MUTTRW5ITVJ?
ES6 NEXMZpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfLTWM2OD1yLkmxNFY3KM7:TR?= MYjTRW5ITVJ?
SNU-387 MnfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTBwOUmzPVMh|ryP NVLFTHI4W0GQR1XS
CMK MmjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfDfIs2UUN3ME2wMlk6QTJ7IN88US=> NFHDR4NUSU6JRWK=
SJSA-1 NF;4UI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHjTJFpUUN3ME2xMlA{PjV|IN88US=> MkXpV2FPT0WU
SIMA MlzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTFwME[4NlUh|ryP Ml;EV2FPT0WU
ES3 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHDTWM2OD1zLkGyNlk4KM7:TR?= M{fN[HNCVkeHUh?=
IGROV-1 NX22Wox2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTFwMUW0OFQh|ryP MYXTRW5ITVJ?
MEL-JUSO NW\uXpJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PKXWlEPTB;MT6xOVc2QSEQvF2= MkThV2FPT0WU
T84 NI\FWWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzSeWNkUUN3ME2xMlIxQTF2IN88US=> NWnuVHhPW0GQR1XS
CAL-85-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTFwMkOxN|gh|ryP M{jzTHNCVkeHUh?=
RD NXG2R4JqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTFwMk[0OVUh|ryP NEK0d2hUSU6JRWK=
TE-8 MmX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXZTWM2OD1zLkOxOFYzKM7:TR?= MlXLV2FPT0WU
L-363 MnPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HZVWlEPTB;MT6zOFIxQCEQvF2= MmS2V2FPT0WU
EKVX NILEZ4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTRTWM2OD1zLkO0OVY5KM7:TR?= NV3zWmZ4W0GQR1XS
SK-MEL-3 NX[wfIx4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrWeYNiUUN3ME2xMlQ5PTV4IN88US=> NIHCe5NUSU6JRWK=
TGBC24TKB MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTFwNUCxPVMh|ryP NUfWcYp7W0GQR1XS
NCI-H1770 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHj6SHBKSzVyPUGuOVEyOTNizszN NYPDTXdjW0GQR1XS
HuH-7 M4TtZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTFwNkCwPVgh|ryP Mlv2V2FPT0WU
HL-60 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTFwNk[5Nlgh|ryP MUjTRW5ITVJ?
TE-1 NHLme3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkSzTWM2OD1zLkewPVQ2KM7:TR?= Mlj4V2FPT0WU
LC-2-ad MnjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXYTHFKSzVyPUGuO|M5QDdizszN NHXLTotUSU6JRWK=
LB647-SCLC NWP4[Wp4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\FTWM2OD1zLke2OVg{KM7:TR?= M1Kx[nNCVkeHUh?=
NCI-H2171 NFja[mlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3vN4t3UUN3ME2xMlc4PzF4IN88US=> NXnB[VFQW0GQR1XS
SK-PN-DW MoHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTFwOUGyPVgh|ryP MoXoV2FPT0WU
MC-IXC MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHi4c4tKSzVyPUGuPVg6QCEQvF2= MmnHV2FPT0WU
LS-513 M1TCWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHlTmhjUUN3ME2yMlA2OzB3IN88US=> NVTTOIc5W0GQR1XS
EW-3 MlPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;md2lEPTB;Mj6wPVg1PCEQvF2= MlO0V2FPT0WU
OPM-2 NH\Tco9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWiyeod7UUN3ME2yMlExOiEQvF2= NWDUT5ZCW0GQR1XS
LP-1 NIL2fpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M12wUmlEPTB;Mj6yOVgxPyEQvF2= MWTTRW5ITVJ?
LU-134-A MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTJwMke3JO69VQ>? M2GzTnNCVkeHUh?=
CP66-MEL NUfBeWFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTJwMkmwNVQh|ryP NX3KbGxCW0GQR1XS
HCC1143 M1j3fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvVZ2xsUUN3ME2yMlQ2OzZ6IN88US=> M2q4dHNCVkeHUh?=
LOXIMVI NFnJOGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPYOFJKSzVyPUKuOlAzOSEQvF2= M4WyNHNCVkeHUh?=
TE-10 M3\u[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fmS2lEPTB;Mj63NFg{QCEQvF2= Mk\vV2FPT0WU
NCI-H1882 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTJwN{WyNlch|ryP NXvDfnlTW0GQR1XS
CHP-126 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPTUmx3UUN3ME2yMlc3OzF5IN88US=> M2jST3NCVkeHUh?=
NCI-H1623 NH3jR4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTJwOUKwNlQh|ryP MkfPV2FPT0WU
GB-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTJwOUO0NFQh|ryP NVL5O4FPW0GQR1XS
RCC10RGB NIrpPJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTJwOUWyPFEh|ryP MlPPV2FPT0WU
NCI-H2141 M1;ld2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvNS49KSzVyPUKuPVY5QTZizszN MVjTRW5ITVJ?
GI-ME-N NUG4SFJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrLNGxKSzVyPUOuNFA2PjVizszN NUfHeIVEW0GQR1XS
NCI-H526 NFu4O5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE[wPWZKSzVyPUOuNFQxQDVizszN MYXTRW5ITVJ?
NCI-H747 MlL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGP6VmhKSzVyPUOuNFQ6QTJizszN NGPYfZRUSU6JRWK=
SNU-423 NEXMWmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUThT3NLUUN3ME2zMlIxOzF|IN88US=> NGHyO2RUSU6JRWK=
A427 NYnUOopIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;v[WlEPTB;Mz6yOVY6QSEQvF2= M1PZZnNCVkeHUh?=
CAL-12T NEPMb|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlW4TWM2OD1|LkSwO|E{KM7:TR?= NXL6WVZtW0GQR1XS
LU-99A NUjUcJNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHhUHZKSzVyPUOuOFcyODVizszN Mn71V2FPT0WU
MS-1 NYL1eGlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTNwNUO0Nlkh|ryP NYDDbHd[W0GQR1XS
SK-LU-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PDdGlEPTB;Mz63OlI6PSEQvF2= M1:zeXNCVkeHUh?=
SW837 NGm1eJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTqTWM2OD1|Lke2N|M{KM7:TR?= M33sRnNCVkeHUh?=
ES8 NXnNN4syT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DLOWlEPTB;Mz64N|g4PyEQvF2= Mn\KV2FPT0WU
MZ2-MEL MlHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTNwOUKwPFYh|ryP MWPTRW5ITVJ?
TGW NUfDUHZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTRwMEGzNVEh|ryP NF3BdoJUSU6JRWK=
GP5d Mon0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHntXo5KSzVyPUSuNFU{PjJizszN MUTTRW5ITVJ?
BB49-HNC MkLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\QflJKSzVyPUSuNVUzOTNizszN Mk\oV2FPT0WU
NB13 NXfwOoUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPrTWM2OD12LkK2PFg4KM7:TR?= NIDuVVJUSU6JRWK=
NTERA-S-cl-D1 NHrOVJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTRwMki2NVUh|ryP NVmyTXl3W0GQR1XS
NCI-H1648 NVz2Ro52T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLTTWM2OD12LkK5PFE6KM7:TR?= MmTzV2FPT0WU
LCLC-103H Ml\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTRwM{KxPVUh|ryP MXXTRW5ITVJ?
LS-411N NH3qWmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3wSW1[UUN3ME20MlQ1QDh3IN88US=> NYraOJZpW0GQR1XS
NCI-H1092 MlLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTRwNEW2PFch|ryP M33HeXNCVkeHUh?=
PANC-10-05 Mn:zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLnTWM2OD12Lk[5PFQh|ryP M2L0THNCVkeHUh?=
DK-MG M2fVb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjmWY5KSzVyPUSuPFA6OzNizszN Mmq3V2FPT0WU
OVCAR-5 M4Cy[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rlVWlEPTB;ND64NVIzPiEQvF2= MYLTRW5ITVJ?
CAL-39 NYTh[pJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rVZWlEPTB;ND64O|Y4KM7:TR?= MnTjV2FPT0WU
TE-441-T MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHPc49KSzVyPUSuPVA2OzdizszN MmjZV2FPT0WU
MOLT-16 M1zLVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrlZ4JzUUN3ME20Mlk2OjV|IN88US=> MVjTRW5ITVJ?
MCF7 MmDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXLeFZ4UUN3ME21MlE1PTF5IN88US=> MYHTRW5ITVJ?
CAPAN-1 MmXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLSUZVKSzVyPUWuNlU4ODdizszN NH3oVXNUSU6JRWK=
PSN1 NGjuNHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXPTWM2OD13LkK3NlM2KM7:TR?= M1zDN3NCVkeHUh?=
NCI-H292 MlPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPTVlhXUUN3ME21MlMxODR2IN88US=> MWjTRW5ITVJ?
CPC-N Ml7jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjmNFZKSzVyPUWuN|k1OTlizszN NVPoeJlsW0GQR1XS
DoTc2-4510 Ml3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTVwNEWzO|Eh|ryP M1LxNnNCVkeHUh?=
LB1047-RCC MlfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXSTWM2OD13LkW1PVM{KM7:TR?= Mnf6V2FPT0WU
MHH-ES-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjRU4hXUUN3ME21MlU6QTB5IN88US=> MXXTRW5ITVJ?
NMC-G1 NHfPNZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETzOVZKSzVyPUWuO|AzOjdizszN M2rRS3NCVkeHUh?=
SW1710 NFXP[o9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIqxO4tKSzVyPUWuO|Q4PTFizszN NVXKbXhVW0GQR1XS
YAPC Mn:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPKTZNUUUN3ME21Mlc3OjBzIN88US=> NUO3[VFuW0GQR1XS
22RV1 Mn\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTVwOECwNVkh|ryP Mor4V2FPT0WU
COLO-679 NVzYbJE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLWTWM2OD13Lki4PVQ5KM7:TR?= M4[2O3NCVkeHUh?=
TCCSUP NV3uRYNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rWW2lEPTB;NT65N|I2QSEQvF2= MXrTRW5ITVJ?
C2BBe1 NX\mWFRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTVwOUO5O{DPxE1? NYXE[IJqW0GQR1XS
TE-15 M4Lsbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXsTWM2OD14LkC2OlA2KM7:TR?= NUDMfXJKW0GQR1XS
SCLC-21H MnnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\Nd|ZKSzVyPU[uNVA5PDNizszN MmHLV2FPT0WU
EoL-1-cell NWHQW|BWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTZwMU[1OlMh|ryP MkfaV2FPT0WU
NKM-1 NGPuN|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnTfINKSzVyPU[uNVY4OSEQvF2= NVXPZWZHW0GQR1XS
NCI-H1304 NVrNRmZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTZwMke0Nlgh|ryP MU\TRW5ITVJ?
NB6 M3nxfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfGdmNKSzVyPU[uNlk3OjJizszN NIjpNWVUSU6JRWK=
NALM-6 MmLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTqTWM2OD14LkOzNlMh|ryP M2njXHNCVkeHUh?=
NCI-H522 NFjvb5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTZwM{OzNFYh|ryP Mme4V2FPT0WU
MV-4-11 M2fUNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnKTWM2OD14LkO3NFc6KM7:TR?= MWDTRW5ITVJ?
LB2241-RCC NHS5[YdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mme4TWM2OD14LkO4OlY4KM7:TR?= M1uzTnNCVkeHUh?=
NCI-H1417 NV\0eoFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DQbWlEPTB;Nj60NFg1PyEQvF2= MXTTRW5ITVJ?
HT-1197 M4jlTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTZwNUexNlIh|ryP M4K4O3NCVkeHUh?=
P30-OHK NV7W[4NHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTZwNkK3O{DPxE1? M1PRSHNCVkeHUh?=
ALL-PO NWPmVVZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\0UolKSzVyPU[uO|E6OTZizszN M3vPWXNCVkeHUh?=
OVCAR-4 NIPEOVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTZwN{W0NFUh|ryP NH7sR4ZUSU6JRWK=
HCC2157 NIXxbWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjKTWM2OD14Lke3OFc2KM7:TR?= MnvPV2FPT0WU
NCI-H838 MlewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M136UmlEPTB;Nj65OlQ6KM7:TR?= NGW1UIdUSU6JRWK=
NCI-H1299 M3Prb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTZwOUewPUDPxE1? M1XQWnNCVkeHUh?=
SW954 NUHCPWRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYX0SGFJUUN3ME23MlIxODZ6IN88US=> M4rwVnNCVkeHUh?=
NCI-H441 NEnrfm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTdwM{SwOlUh|ryP NGnJOJdUSU6JRWK=
SK-MEL-2 M{P0VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHDNlNKSzVyPUeuOFg{PzNizszN MVnTRW5ITVJ?
KARPAS-45 NH21OnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlz4TWM2OD15Lk[1PVI6KM7:TR?= Ml3iV2FPT0WU
CAL-54 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE[5fVZKSzVyPUeuPFI6PzdizszN MX3TRW5ITVJ?
KYSE-180 NHizN3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXu2OZVNUUN3ME23Mlg5QTRzIN88US=> M1LxW3NCVkeHUh?=
NCI-H187 M13Cbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzjNHVKSzVyPUeuPVU6PDdizszN MUfTRW5ITVJ?
RT-112 NEDEdYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XQOGlEPTB;OD6wPVY4PyEQvF2= MVPTRW5ITVJ?
NCI-H1437 MmH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLuNWVpUUN3ME24MlA6Pzl3IN88US=> NXPJO3pFW0GQR1XS
SNU-449 M1nOSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{S5VWlEPTB;OD6yPFI4OiEQvF2= NIK2[|hUSU6JRWK=
HCC1187 M{TnPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nMS2lEPTB;OD6yPVM6OSEQvF2= M1;UeHNCVkeHUh?=
NCI-H2030 Mm\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXybGpGUUN3ME24MlM4PzF2IN88US=> Moq1V2FPT0WU
HuO-3N1 NHG3XGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFL3bINKSzVyPUiuN|c5PDRizszN NGLGepZUSU6JRWK=
COLO-792 NULF[|duT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfKRXVKSzVyPUiuOFE2OjdizszN NHKx[FdUSU6JRWK=
MIA-PaCa-2 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33XbGlEPTB;OD64OVUxQCEQvF2= MW\TRW5ITVJ?
SK-N-FI MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTlwMESyOUDPxE1? NYjENGFRW0GQR1XS
MMAC-SF NEe5ZnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTlwMEm3OVEh|ryP M3niSnNCVkeHUh?=
NCI-H28 MkLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\PN4RQUUN3ME25MlExPDZ7IN88US=> M4i0dHNCVkeHUh?=
ETK-1 M4jSZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzKTWM2OD17LkK5PVc1KM7:TR?= MmnsV2FPT0WU
NCI-H1993 MmnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\wSoM2UUN3ME25MlQ1OjZzIN88US=> NULJS|VyW0GQR1XS
no-11 NInjRZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LpUWlEPTB;OT60O|EzKM7:TR?= NXKzWmZSW0GQR1XS
ChaGo-K-1 NXfp[nA{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXoNnRKSzVyPUmuOVE2QDNizszN MmPNV2FPT0WU
NCCIT NHnn[W9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTlwNUOxOlkh|ryP Mmj0V2FPT0WU
SAS NWOwV|ROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTFyLkK0PEDPxE1? NUjvc5JpW0GQR1XS
A673 NF:5fHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLBWHlKSzVyPUGwMlM4ODRizszN MonoV2FPT0WU
NCI-H1522 NGXEbJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTFyLkO3NFch|ryP NFHzR2tUSU6JRWK=
NCI-H810 MlW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTFyLkO5NFch|ryP MUfTRW5ITVJ?
IST-MES1 M173Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\GTWM2OD1zMD60OVY1KM7:TR?= NFK4blJUSU6JRWK=
GR-ST MmLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTFyLkWwNlQh|ryP MXnTRW5ITVJ?
SUP-T1 MojxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rlV2lEPTB;MUCuO|MyPyEQvF2= NVjRT2l5W0GQR1XS
NB5 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nGTGlEPTB;MUCuPVAzOiEQvF2= MnfoV2FPT0WU
MZ1-PC M1vJ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjJO2JKSzVyPUGwMlk2PzFizszN Mm[2V2FPT0WU
SK-CO-1 NI[2NGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkP3TWM2OD1zMD65PVMyKM7:TR?= NETNVZpUSU6JRWK=
Capan-2 MlzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTRbYhoUUN3ME2xNU4{OTl6IN88US=> NYmxV2FDW0GQR1XS
697 NGfsO5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{G4TWlEPTB;MUGuOlc2PyEQvF2= NXO2OWN6W0GQR1XS
REH NETRWm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTFzLke0OVEh|ryP MXLTRW5ITVJ?
GI-1 NIXVU5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfvVVRKSzVyPUGxMlg3OTVizszN MYnTRW5ITVJ?
BB65-RCC Ml\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\kUmF1UUN3ME2xNk4xQTF4IN88US=> NFKwZmNUSU6JRWK=
NCI-H1651 Ml3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYmycJFpUUN3ME2xNk4zPDd6IN88US=> MUTTRW5ITVJ?
NCI-H1618 M3vvWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HXVWlEPTB;MUKuN|k4PiEQvF2= NVzQd4R7W0GQR1XS
NCI-H2081 MnHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\QUZVKSzVyPUGyMlYyPDFizszN NUW5flNXW0GQR1XS
GCIY NVfhRmJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFSxblNKSzVyPUGyMlczOTNizszN MYrTRW5ITVJ?
NY NHXYUFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTF|LkC2OFMh|ryP NV\J[XNkW0GQR1XS
PANC-03-27 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDPVoNKSzVyPUGzMlA5ODdizszN NYj0UJlyW0GQR1XS
BHY M3zHfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXqTWM2OD1zMz6yNVIyKM7:TR?= M{fxSXNCVkeHUh?=
SK-OV-3 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTF|LkO3OlMh|ryP MWPTRW5ITVJ?
5637 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTF|Lke3OVkh|ryP M1jtUnNCVkeHUh?=
LC-1F NWq4NWd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XGWmlEPTB;MUSuNFM2PiEQvF2= MXfTRW5ITVJ?
SNB75 NGDYXHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTF2LkCzPFMh|ryP MnrSV2FPT0WU
CHP-212 NHjFdmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fyV2lEPTB;MUSuNFQ3PCEQvF2= Mn3YV2FPT0WU
HT-1376 NWLQU40xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTF2LkGxNlYh|ryP NFX0dm1USU6JRWK=
MONO-MAC-6 MlXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XZWGlEPTB;MUSuNVUxOiEQvF2= M4XueXNCVkeHUh?=
CA46 M{XmRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfZTWM2OD1zND6xPFI4KM7:TR?= MVLTRW5ITVJ?
SCC-15 NFnoR4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHiepU3UUN3ME2xOE42PTh|IN88US=> NGPNOopUSU6JRWK=
ATN-1 MonMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHYTWM2OD1zND62OlI4KM7:TR?= NYPtT3lyW0GQR1XS
NCI-H2405 NEe3b4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYD1TVdzUUN3ME2xOE45OTV5IN88US=> M4LLd3NCVkeHUh?=
NCI-H716 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DTSGlEPTB;MUSuPFQ6OyEQvF2= MYnTRW5ITVJ?
SW620 NGnFSmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HDTWlEPTB;MUSuPVAyPCEQvF2= NWK1VpFkW0GQR1XS
NCI-H226 NEmySlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETORnZKSzVyPUG0MlkxQDVizszN NGDGWXJUSU6JRWK=
SW962 M1PxcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjUV4tKSzVyPUG0Mlk1OzJizszN M3vmVHNCVkeHUh?=
KYSE-150 MoDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTF2Lkm1OUDPxE1? MUfTRW5ITVJ?
OCUB-M M4PEeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknSTWM2OD1zND65PFg{KM7:TR?= NWXkc5M{W0GQR1XS
ES7 NUnyb4h1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fzS2lEPTB;MUWuNFk5PCEQvF2= NX3ldphLW0GQR1XS
SW1463 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTF3LkSyNlMh|ryP NE[xZVhUSU6JRWK=
CAKI-1 M3nKRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTF3LkWzOFYh|ryP NHnhd|NUSU6JRWK=
MKN28 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzsTWM2OD1zNT61OFc6KM7:TR?= NWDuT2t2W0GQR1XS
SW13 MlXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PhOmlEPTB;MUWuOlE5KM7:TR?= NITyWVVUSU6JRWK=
A3-KAW M133[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPwTWM2OD1zNT65Olk4KM7:TR?= M3[0c3NCVkeHUh?=
LU-65 NV;KeGRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnIUWNKSzVyPUG1Mlk4PjhizszN MXzTRW5ITVJ?
Calu-1 M2\mXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jp[WlEPTB;MU[uNFM3QCEQvF2= MnztV2FPT0WU
ST486 MmXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTF4LkC0N|Eh|ryP M1TsRXNCVkeHUh?=
BB30-HNC MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrHPVVKSzVyPUG2MlEzPDZizszN MVrTRW5ITVJ?
EGI-1 Mn3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTF4LkS0OkDPxE1? MXrTRW5ITVJ?
SH-4 Mnq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWC1cW1IUUN3ME2xOk41PzNzIN88US=> M1jERXNCVkeHUh?=
MN-60 MnXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XteWlEPTB;MUeuNlI6PyEQvF2= MnjIV2FPT0WU
MPP-89 NG[xfpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2Xn[WlEPTB;MUeuNlQ2QSEQvF2= NXjhTHNtW0GQR1XS
A2780 M1n0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTF5LkSxN|kh|ryP NXO0VoJlW0GQR1XS
Daoy MmXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjFNG16UUN3ME2xO{41Pjl3IN88US=> NETL[mlUSU6JRWK=
NCI-H2126 Mlm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYq1eYxiUUN3ME2xO{41PzdzIN88US=> NVzFeG9sW0GQR1XS
NCI-H1563 NWTmR5FjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofRTWM2OD1zNz60PVE4KM7:TR?= MYXTRW5ITVJ?
8-MG-BA NYnPW2M{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn:xTWM2OD1zNz62OlQ5KM7:TR?= NYHlOJdqW0GQR1XS
786-0 MkXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTF5LkizOVMh|ryP M3f0WnNCVkeHUh?=
AM-38 MoO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTF5LkmzNFYh|ryP M33mcXNCVkeHUh?=
COLO-824 M1foXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWe2NnlPUUN3ME2xPE41PDN4IN88US=> M3ztcXNCVkeHUh?=
SK-MEL-30 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTF6LkWwPFIh|ryP Ml\iV2FPT0WU
CESS NFW5W4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF2wV49KSzVyPUG4Mlc3ODlizszN M2XtfnNCVkeHUh?=
BL-70 MmeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjGTWM2OD1zOD64NVU3KM7:TR?= MnrYV2FPT0WU
NCI-H2170 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfBTWM2OD1zOD65NVc6KM7:TR?= MlTrV2FPT0WU
HT-3 MojCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvQTWM2OD1zOD65PFMh|ryP M4G5NHNCVkeHUh?=
BOKU NF\hU5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XhfWlEPTB;MUmuNFM5OSEQvF2= M1XRe3NCVkeHUh?=
HPAF-II MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HCdGlEPTB;MUmuN|AyPSEQvF2= NXq5XoVMW0GQR1XS
KGN NGXZWpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\sb4ZKSzVyPUG5MlQ4PjVizszN NH;2ToRUSU6JRWK=
MC-CAR NIPTOZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTF7Lk[zNVMh|ryP NVrxN29kW0GQR1XS
BHT-101 MmTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fLOmlEPTB;MUmuO|c4KM7:TR?= NGf6O3JUSU6JRWK=
SW1783 NIDRTJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHJb4lKSzVyPUG5Mlc5ODZizszN Ml\5V2FPT0WU
KP-N-YN NFPHWmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4ryOGlEPTB;MkCuNFI3OiEQvF2= MojTV2FPT0WU
LU-165 M3X1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnjPYlwUUN3ME2yNE42PTdzIN88US=> MXXTRW5ITVJ?
GOTO NYXUco9qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYq3UIcxUUN3ME2yNE43PDVzIN88US=> M4fOfXNCVkeHUh?=
EFM-19 M2TjOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HO[WlEPTB;MkGuNFcyPiEQvF2= NGP5XnhUSU6JRWK=
CTV-1 NWLmVnR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTJzLkGwOVQh|ryP M{HvTnNCVkeHUh?=
HEL Mn3US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjH[HVwUUN3ME2yNU41OjF4IN88US=> M3jP[XNCVkeHUh?=
SNU-C2B MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrvRolUUUN3ME2yNU41OjZizszN NV;nTHE1W0GQR1XS
ECC4 M37ne2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDLO2sxUUN3ME2yNU44ODdizszN NFzIN3ZUSU6JRWK=
NEC8 NWOwe|RPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTJzLkizOlgh|ryP M1fpRXNCVkeHUh?=
KMOE-2 NFWwdnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDsfZVKSzVyPUKxMlg6OjFizszN MUXTRW5ITVJ?
NCI-H524 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPkbHVKSzVyPUKyMlA5ODhizszN M4rpdnNCVkeHUh?=
WSU-NHL NXW5d5N[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vt[WlEPTB;MkKuNVU4PyEQvF2= M4T2cnNCVkeHUh?=
SF126 M1zhd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTJ{LkK0Olkh|ryP NIO5e4hUSU6JRWK=
HOP-92 NGLmS3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LnT2lEPTB;MkKuN|E3PyEQvF2= NWm5N286W0GQR1XS
CTB-1 M2Dlb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTJ{LkS2O|ch|ryP MmHYV2FPT0WU
KYSE-270 NXfNcoI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTJ{LkmzOVch|ryP NX65ZnlSW0GQR1XS
SK-MEL-24 M{PxU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DMWWlEPTB;MkOuNVg4KM7:TR?= MmHiV2FPT0WU
Calu-3 NUW1cXFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLWb|JKSzVyPUKzMlIyOjhizszN MVrTRW5ITVJ?
GAMG MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGO0e|RKSzVyPUKzMlI{PjdizszN M2XYVnNCVkeHUh?=
SW1573 M1nNWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3wPGpKSzVyPUKzMlc1OTVizszN NWD4TZNJW0GQR1XS
MHH-NB-11 NWP6dG1iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnzUFdkUUN3ME2yOE4xOTl2IN88US=> NHjhWlBUSU6JRWK=
TK10 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITJXlJKSzVyPUK0MlUxOTNizszN M2nleXNCVkeHUh?=
LB373-MEL-D MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTJ2Lk[wOlQh|ryP M1S4dXNCVkeHUh?=
KALS-1 NXzDZ4Z[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\LOolzUUN3ME2yOE44OzJ5IN88US=> NV;4PWFWW0GQR1XS
HUTU-80 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEeyd2hKSzVyPUK1MlgxOzJizszN M3jhc3NCVkeHUh?=
HuP-T3 M{\qUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTJ4LkG2O|Qh|ryP NFWzNVFUSU6JRWK=
OE19 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnVbox{UUN3ME2yOk4zOTV|IN88US=> MknKV2FPT0WU
J82 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTJ4LkK0O|Eh|ryP M4nKNHNCVkeHUh?=
DU-4475 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\P[WE3UUN3ME2yOk4{QDF7IN88US=> MUHTRW5ITVJ?
DMS-53 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWL0dZRXUUN3ME2yOk42OTN6IN88US=> NIW2cYFUSU6JRWK=
COLO-741 NF75e3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkftTWM2OD1{Nj64N|Q1KM7:TR?= MUTTRW5ITVJ?
SW48 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmryTWM2OD1{Nj64PFIh|ryP MmXhV2FPT0WU
IGR-1 NHTVPItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTJ4LkmzN|Qh|ryP NXLHV5VtW0GQR1XS
639-V M1\6dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HySWlEPTB;MkeuNFI1PSEQvF2= NWjpOGF1W0GQR1XS
LK-2 M17jNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHFTWM2OD1{Nz60NVQyKM7:TR?= NUjnNoZNW0GQR1XS
NCI-H2347 MlXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHKTWM2OD1{Nz65Olk6KM7:TR?= MmDaV2FPT0WU
NCI-H2228 M2fGUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzQbnpKSzVyPUK4MlA6ODVizszN MXTTRW5ITVJ?
LS-123 MlvPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPOU|VKSzVyPUK4MlEzPjJizszN NWm1R2hPW0GQR1XS
U031 Ml34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTJ6LkK1NkDPxE1? NYHFeFl[W0GQR1XS
NCI-H1792 NYLOOpBnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTJ6LkS3NlEh|ryP MlnuV2FPT0WU
NCI-H2087 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXyUmdKSzVyPUK4Mlc2PTJizszN MlX0V2FPT0WU
NCI-H2342 MkDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnzTnRHUUN3ME2yPU42OjB6IN88US=> NX3jT3c3W0GQR1XS
SW626 M{my[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TabmlEPTB;MkmuO|U3KM7:TR?= NHXMeVhUSU6JRWK=
LB2518-MEL MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TjRWlEPTB;MkmuPFE2KM7:TR?= M1vEeXNCVkeHUh?=
RXF393 NGjRdYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;YTWM2OD1|MD6wPVUzKM7:TR?= MnPyV2FPT0WU
LC4-1 M1rNRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUm3RYhCUUN3ME2zNE4{ODl{IN88US=> MnLkV2FPT0WU
NCI-H1694 M3i0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnP[|hKSzVyPUOwMlY3OjRizszN MVHTRW5ITVJ?
K5 M3zNNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLJeHNNUUN3ME2zNE46PzB{IN88US=> NFPSeoJUSU6JRWK=
HDLM-2 MmXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnXTWM2OD1|MD65O|I2KM7:TR?= NHHRWolUSU6JRWK=
BCPAP MnjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTNzLkizO|kh|ryP NGS5c|hUSU6JRWK=
BC-3 NUXNVldFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFSzWXFKSzVyPUOyMlE1ODNizszN M3LsZ3NCVkeHUh?=
LB996-RCC M1jTS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zMNmlEPTB;M{KuNlM2QCEQvF2= M2LkSXNCVkeHUh?=
NCI-H2009 Mmm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzZXGlwUUN3ME2zNk41QThzIN88US=> NYf6S3hTW0GQR1XS
HTC-C3 MoX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETqdoVKSzVyPUOzMlc2OTlizszN NGnuSGNUSU6JRWK=
LAMA-84 NX75[nRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTN2LkS0NFch|ryP NIe5R3dUSU6JRWK=
CCRF-CEM NXrCR2ttT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzpTWM2OD1|ND61O|E2KM7:TR?= Ml[2V2FPT0WU
AN3-CA M4C0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkf4TWM2OD1|NT6wOVY5KM7:TR?= Mkf4V2FPT0WU
NCI-H1734 NV3PTnpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPXTWM2OD1|NT6yOVYyKM7:TR?= NYPpXIEyW0GQR1XS
Ca-Ski M3jMcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXxTWM2OD1|NT60NVAyKM7:TR?= M{TMVXNCVkeHUh?=
U-266 Mn7jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7B[HFZUUN3ME2zOU43OTF2IN88US=> MUDTRW5ITVJ?
SBC-5 NFjDRZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPGcohnUUN3ME2zOU44PzhzIN88US=> MV;TRW5ITVJ?
GT3TKB NEnnZVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnkU3FKSzVyPUO3MlEyPSEQvF2= NWjab|dyW0GQR1XS
MDA-MB-175-VII MkizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTN5LkKyOFgh|ryP NIGyWnFUSU6JRWK=
PFSK-1 MnnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrqe5E4UUN3ME2zO{4zPDN3IN88US=> M2PMT3NCVkeHUh?=
IMR-5 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTN5LkK0PFch|ryP NHzReINUSU6JRWK=
Daudi MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTN5LkO1PVch|ryP NYn2PZNMW0GQR1XS
A498 NVTRclR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnNTWM2OD1|Nz63NlE5KM7:TR?= Mn65V2FPT0WU
SCC-4 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHpd2VSUUN3ME2zO{44QDR|IN88US=> M33aVXNCVkeHUh?=
COLO-680N MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTN6LkK4PFUh|ryP Ml7YV2FPT0WU
SK-MES-1 M{\zOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTN6LkOyNVUh|ryP NHfWSopUSU6JRWK=
SR MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\RWHBKSzVyPUO4MlU1QTVizszN M{D5TnNCVkeHUh?=
LNCaP-Clone-FGC MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITYdJdKSzVyPUO4MlU3OzdizszN MUfTRW5ITVJ?
SK-HEP-1 M1PqOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTN6Lke4NlIh|ryP NXfze4czW0GQR1XS
BPH-1 NVrLe3dQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHBdYRKSzVyPUO4Mlg{OjlizszN NYXaWVFOW0GQR1XS
NCI-H1755 NEW2W25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXzcXpKSzVyPUO5MlU5OTdizszN MlLRV2FPT0WU
LXF-289 M{POT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrPRWw3UUN3ME2zPU45ODh2IN88US=> MYTTRW5ITVJ?
SW1088 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2L5SWlEPTB;NECuNlExPyEQvF2= MXTTRW5ITVJ?
MOLT-4 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrnVIR[UUN3ME20NE4zQTBzIN88US=> MlXBV2FPT0WU
AsPC-1 MlO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTRyLkS1PFMh|ryP NX7Re3FrW0GQR1XS
HOP-62 NW[zW|c1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTRyLk[1Olgh|ryP MoLiV2FPT0WU
A172 M{DUPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXIcYVKSzVyPUSwMlg2OTFizszN NXS3cohvW0GQR1XS
SN12C NXPtdWxDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\5TWM2OD12MD65N|g2KM7:TR?= MYTTRW5ITVJ?
MDA-MB-231 M1;5Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3XTWM2OD12MD65PFk5KM7:TR?= M3XXNHNCVkeHUh?=
RPMI-2650 MlXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnVTWM2OD12MT6xOVk{KM7:TR?= MlPSV2FPT0WU
KYSE-140 M2Xnbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fYU2lEPTB;NEGuPFEzOyEQvF2= MV\TRW5ITVJ?
KINGS-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTR{LkS2PVch|ryP Ml7kV2FPT0WU
HSC-3 MkfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTR{Lk[2OlEh|ryP MkLCV2FPT0WU
PC-14 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInKemtKSzVyPUSzMlE5QDJizszN NHjXPGpUSU6JRWK=
COR-L105 NXXI[pk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTR|Lk[1NFIh|ryP MUTTRW5ITVJ?
BE-13 NWm4[YNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoH3TWM2OD12ND6yN|cyKM7:TR?= M3XqbHNCVkeHUh?=
NCI-H661 M1ezdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTR2LkK5OVgh|ryP M162b3NCVkeHUh?=
IST-MEL1 NYXZPVUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDtW21jUUN3ME20OE4{PTl7IN88US=> M4TWO3NCVkeHUh?=
HCC1806 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLWTWM2OD12ND61PFc{KM7:TR?= M{j0fHNCVkeHUh?=
COLO-800 NFzuVotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG[5UGJKSzVyPUS0Mlg1PTNizszN NXvlfHlPW0GQR1XS
IST-SL2 MmPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3uxSWlEPTB;NEWuNVI1PyEQvF2= MWDTRW5ITVJ?
8305C Mm\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXnfodKSzVyPUS1MlMxQSEQvF2= MXPTRW5ITVJ?
UACC-62 NYLGcJFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX73b2RyUUN3ME20Ok4zQDd3IN88US=> NEfjWpFUSU6JRWK=
COR-L23 NYfvcIlOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTR5LkG5PUDPxE1? NWXxWVF6W0GQR1XS
EFE-184 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTR5LkO4PEDPxE1? MmnhV2FPT0WU
DMS-114 MoLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHVPJhKSzVyPUS3MlQyPDlizszN Mle3V2FPT0WU
KYSE-520 NUXQS4VxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoT2TWM2OD12OD61N|E2KM7:TR?= Ml3FV2FPT0WU
SNG-M MorGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\0[JdKSzVyPUS5MlQ{PCEQvF2= NFXoflFUSU6JRWK=
A2058 MlvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HBbWlEPTB;NEmuOFg5PSEQvF2= NVfUXot1W0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo試験 OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the Vmax is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. [1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. [2]
臨床試験 OSI-906 is currently under a Phase III clinical trial in adrenocortical carcinoma (ACC).
特集

プロトコル (参考用のみ)

キナーゼアッセイ: [1]

Protein kinase biochemical assays Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log10 compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerProTM Kinase Selectivity Assay Kit.

細胞アッセイ: [1]

細胞株 MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells
濃度 0.02-0.8 μM
反応時間 3 days
実験の流れ For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only.

動物実験: [1]

動物モデル IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model
製剤 25 mM tartaric acid
投薬量 25 mg / kg and 75 mg / kg
投与方法 Orally administrated at once-daily oral dose for 14 days

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download OSI-906 (Linsitinib) SDF
分子量 421.49
化学式

C26H23N5O

CAS No. 867160-71-2
保管 2年-20℃
6月-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 84 mg/mL (199.29 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo 30% PEG400/0.5% Tween80/5% propylene glycol 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 (1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutanol

カスタマーフィードバック (3)


Click to enlarge
Rating
Source Cancer Res, 2013, 73, 834-843. OSI-906 (Linsitinib) purchased from Selleck
Method Cell proliferation and growth assays
Cell Lines PFR3 cells
Concentrations 1 μM
Incubation Time
Results The IC50 of PFR3 cells for PF299804 was more than 100 fold lower with the combination of OSI-90 than with PF00299804 alone.

Click to enlarge
Rating
Source Cancer Res, 2011, 71, 6773-84. OSI-906 (Linsitinib) purchased from Selleck
Method [18 F]FDG –PET/ Western blot
Cell Lines MCF-7 cells/athymic mice
Concentrations 50 mg/kg/day
Incubation Time 6 weeks
Results mice without palpable tumors were randomized to treatment with vehicle or OSI-906. Six of 20 control mice (30%) developed tumors, whereas none of the 20 OSI-906–treated mice did (Fig. A). OSI-906 inhibited tumor growth compared with vehicle (Fig. B; P < 0.05). OSI-906–treated tumors exhibited markedly lower levels of phosphorylated IGF-IR, InsR, IRS-1, AKT, and S6 compared with vehicle controls (Fig. C). FDG uptake was significantly decreased 4 hours after a single dose of OSI-906 com-pared with baseline (Fig. D)

Click to enlarge
Rating
Source OSI-906 (Linsitinib) purchased from Selleck
Method Flow cytometry/ Western Blotting
Cell Lines CLL B cells
Concentrations 1 µM
Incubation Time 24 h
Results three structurally unrelated IGF1R inhibi tors AG1024, Picropodophyllin (PPP) and linsitinib significantly reduced the cellular viability of primary CLL cells ( Figure A) and reduced levels of phosphorylated IGF1R and IRS-1 (Figure B,C). AG1024, which showed the strongest effect on viability, caused a dose-dependent decrease in the levels of phosphorylated Src, PI3K, Akt, MEK and ERK (Figure D).

文献中の引用 (15)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related IGF-1R 阻害剤

  • Picropodophyllin (PPP)

    Picropodophyllin (PPP) is a selective IGF-1R inhibitor with IC50 of 1 nM. Phase 1/2.

  • Erlotinib

    Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • R428 (BGB324)

    R428 (BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).

  • Pexidartinib (PLX3397)

    Pexidartinib (PLX3397) is an oral, potent mutil-targeted receptor tyrosine kinase inhibitor of CSF-1R, Kit, and Flt3 with IC50 of 20 nM, 10 nM and 160 nM, respectively. Phase 3.

  • BMS-536924

    BMS-536924は、ATP競争的IGF-IRとIR阻害剤で、IC50 がそれぞれ 100 nM と 73 nMです。

  • NVP-AEW541

    NVP-AEW541は、IGF-IRとInsRの二重阻害剤で、IC50 がそれぞれ 86 nM と 140 nMです。

  • NVP-ADW742

    NVP-ADW742は、0.17のμMのIC50によるIGF1R阻害剤です。

  • GSK1904529A

    GSK1904529Aは選択性阻害剤、(IGF-IR) と (IR)を抑制する時、 IC50が それぞれ27 nM と 25 nMになる.

  • BMS-754807

    BMS-754807は、IGF1R/IR家族キナーゼの強力で可逆的な阻害剤で、 IGF-1RIRMetTrkATrkBを妨げ、IC50 がそれぞれ 1.8 nM、1.7 nM、5.6 nM、7.4 nM 、 4.1 nMです。

    Features:Muti-inhibitor of the IGR-1R/IR family.

最近チェックしたアイテム

Tags: OSI-906 (Linsitinib)を買う | OSI-906 (Linsitinib)供給者 | OSI-906 (Linsitinib)を購入する | OSI-906 (Linsitinib)費用 | OSI-906 (Linsitinib)生産者 | オーダーOSI-906 (Linsitinib) | OSI-906 (Linsitinib)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ